Pfizer announced Wednesday it has begun phases 2 and 3 of its pediatric clinical trial for Paxlovid, its COVID-19 antiviral treatment.
The study will look into how effective and safe the treatment is for children between the ages of 6 and 17.
The FDA has already authorized Paxlovid for high-risk people who are 12 years or older and weigh at least 88 pounds.Adult trials showed that the antiviral treatment reduced the risk of hospitalization or death by 89% among high-risk adults, according to Pfizer. The company says data from this new trial will “provide further support for the dose recommendations in this population, as well as potentially expand the indication to younger age groups and lower weights."Researchers at Pfizer are also working on formulating an appropriate dose for children as young as 6 years old.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer begins next phase of COVID-19 pill trial for childrenThe company announced Wednesday that it has started the second and third test phases for Paxlovid in children ages 6 to 17.
Read more »
Pfizer launches clinical trial testing its COVID-19 pill in children aged 6 and older
Read more »
Pfizer Starts Testing Its Covid-19 Pill in ChildrenPfizer expects results from its study of the Covid-19 drug Paxlovid in high-risk children by the end of the year
Read more »
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »